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Seasonality of 278 neuromyelitis optica
relapses in a Brazilian cohort
Sazonalidade de 278 surtos em pacientes brasileiros com neuromielite óptica
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Neuromyelitis optica (NMO) is and autoimmune disease
with distinct, clinical, radiological and genetic profile when
compared to multiple sclerosis (MS)1 and, although much
is known about its pathophysiology, the influence of envir-
onmental factors in patients with NMO is not well estab-
lished as in MS2. It has been previously demonstrated that
patients with MS present a higher birth prevalence for
months in the spring and summer, as well as there is a
higher prevalence of MS relapses in these same months3,4,
but the monthly rate of relapses in patients with NMO has
been described in only one study with distinct result from
MS5 and has not been confirmed with further studies.
To evaluate if there is any yearly variation in the incidence
of relapses in patients with NMO, we reviewed our historical
series published in 20096, as it contains detailed information
of all relapses suffered by each patient and added information
on 8 patients from a pediatric NMO cohort that is under
review in our center. All patients received regular preventive
therapies recommended at the time they were seen, which
included, corticosteroids, azathioprine, cyclophosphamide,
methotrexate, plasma exchange and IV immunoglobulin7.
This work is part of an continuous observational project at
the Universidade Federal de São Paulo, has received local ethic
committee approval and patients have given informed con-
sent for retrospective and prospective data collection.
We retrieved 282 relapses from the 49 patients (41 with
adult onset, 41% NMO-IgG+; and 8 with pediatric onset,
75% NMO-IgG+) with relapsing NMO, but analyzed only 278
relapses (98%), as four of them did not have the month of
occurrence available in their medical record. The adult onset
information was retrieved from the historical cohort seen
from 1994 to 20076 and the pediatric onset patients were seen
from 2002 to 2013. The statistical analysis was performed
using Prism 5 (GraphPad Software Incorporated1); relapses
were pooled in two groups representing seasonality already
observed in MS studies4: spring/summer and fall/winter
months. The Kolmogorov-Smirnov test was used to confirm
a normal distribution of the sample and the unpaired t test
performed for comparing both groups.
The seasonality for the 278 relapses analyzed was: 21%
in spring (September - November), 24% in summer
(December - February), 27% in fall (March - May) and 28%
in winter (June - August) (Figure). Although there seemed
to be a higher incidence of relapses in the fall/winter months
as opposed to spring/summer (55% x 45%), this difference did
not reach statistical significance (p = 0.11, unpaired t test
comparing relapses grouped in spring/summer and fall/win-
ter months), disclosing no differences along the year. This lack
of variation could be due to low sunlight exposure variation
(if indeed there really is some seasonality influence on
NMO relapses), as the city of São Paulo is located in a
subtropical climate zone with low sunlight variation when
compared to higher latitude cities (Latitude -23o 32’ 51’’S,
Longitude -46o 38’ 10’’W, 760 meters above sea level), or sim-
ply signifies that sun exposure does not influence relapses in
NMO as it does in MS, as also observed by Muto et al in
Japan5. A similar analysis with MS patients from Campinas,
a city located less than 100 km from Sao Paulo disclosed
higher relapse incidence in the summer/spring months, sug-
gesting that climate variation in the southeast of Brazil can
influence disease activity as elsewhere4, corroborating the idea
that climate might not influence NMO relapses. Since this
analysis comes from a historical cohort, information on
vitamin D levels was not available and this should be prospec-
tively evaluated together with other factors, such as the asso-
ciation to common infection and physical and psychological
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stress factors. Most of these patients received regular immu-
nosuppressive treatment with azathioprine with or without
prednisone as part of our regular treatment protocol, with
76% response7, and thus treatment biases is expected to not
have influenced these results.
In summary, we have evaluated 278 relapses from 49
patients with NMO and demonstrate no association
between relapse incidence and seasonal variation, which is
distinct to MS.
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Figure: Relapse incidence according to month and season in 49 patients with NMO.
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